NO20074267L - Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid - Google Patents

Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid

Info

Publication number
NO20074267L
NO20074267L NO20074267A NO20074267A NO20074267L NO 20074267 L NO20074267 L NO 20074267L NO 20074267 A NO20074267 A NO 20074267A NO 20074267 A NO20074267 A NO 20074267A NO 20074267 L NO20074267 L NO 20074267L
Authority
NO
Norway
Prior art keywords
biologically active
life
modified
polypeptide
conjugates
Prior art date
Application number
NO20074267A
Other languages
English (en)
Norwegian (no)
Inventor
Marc Besman
Stewart Chipman
David Leung
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of NO20074267L publication Critical patent/NO20074267L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20074267A 2005-01-25 2007-08-21 Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid NO20074267L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64711905P 2005-01-25 2005-01-25
US71258505P 2005-08-30 2005-08-30
PCT/US2006/002501 WO2006081249A2 (en) 2005-01-25 2006-01-25 Conjugates of biologically active proteins having a modified in vivo half-life

Publications (1)

Publication Number Publication Date
NO20074267L true NO20074267L (no) 2007-09-28

Family

ID=36644921

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074267A NO20074267L (no) 2005-01-25 2007-08-21 Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid

Country Status (14)

Country Link
US (2) US8129348B2 (pt)
EP (1) EP1841787A2 (pt)
JP (2) JP5735194B2 (pt)
KR (1) KR101608083B1 (pt)
CN (1) CN103172747A (pt)
AU (1) AU2006208199B2 (pt)
BR (1) BRPI0606934A2 (pt)
CA (1) CA2595695A1 (pt)
IL (1) IL184763A (pt)
MX (1) MX2007008982A (pt)
NO (1) NO20074267L (pt)
NZ (1) NZ556726A (pt)
RU (1) RU2007132188A (pt)
WO (1) WO2006081249A2 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0606934A2 (pt) * 2005-01-25 2017-07-11 Cell Therapeutics Inc Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2402754B2 (en) † 2006-03-06 2023-07-26 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
AU2007223855B2 (en) * 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
AU2013203326B2 (en) * 2007-06-21 2013-08-01 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
EP2197897A4 (en) * 2007-08-30 2012-08-08 Univ Waterloo AMINO ACID-BASED SELF-ASSOCIATED PEPTIDES AND METHODS
CN103864895A (zh) 2008-12-29 2014-06-18 隆萨布莱纳公司 制备比伐卢定的方法
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
JP5499296B2 (ja) * 2009-02-03 2014-05-21 国立大学法人東京農工大学 細胞の吸着を制御可能なポリペプチド
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CA2771999A1 (en) * 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
KR102121086B1 (ko) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN104988107B (zh) * 2015-05-19 2018-06-08 中国农业科学院兰州兽医研究所 一种高效表达口蹄疫病毒抗原基因的重组乳酸杆菌及其制备方法和应用
ES2784603T3 (es) * 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
MX2019008827A (es) 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
AU2018393111B2 (en) 2017-12-21 2025-07-10 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
CA3145425A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
JP7398716B2 (ja) * 2019-11-05 2023-12-15 国立大学法人京都大学 ペプチド、組成物、及び、気分障害を治療、予防、又は改善する方法
CN112608366B (zh) * 2020-12-31 2024-08-30 中国药科大学 超正电荷聚多肽及其制备方法、应用
CN113480667B (zh) * 2021-08-17 2023-03-28 长春萤火虫生物科技有限公司 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
WO2024128079A1 (ja) * 2022-12-16 2024-06-20 東亞合成株式会社 合成ペプチド及び構築物
CN120112542A (zh) * 2023-09-27 2025-06-06 京东方科技集团股份有限公司 针对亨廷顿舞蹈症的早期诊断的多肽探针和试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JP3045539B2 (ja) * 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6455678B1 (en) 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
CN1240479A (zh) * 1996-07-09 2000-01-05 安姆根有限公司 截短的可溶性肿瘤坏死因子i－型和ii－型受体
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
ES2341217T3 (es) 1999-01-19 2010-06-17 Maxygen, Inc. Recombinacion de acidos nucleicos mediada por oligonucleotidos.
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
CA2412882A1 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
CA2513287A1 (en) 2002-01-14 2003-07-17 William Herman Multispecific binding molecules
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
ZA200707006B (en) * 2005-01-25 2008-11-26 Cell Therapeutics Inc Conjugates of biologically active proteins having a modified in vivo half-life
BRPI0606934A2 (pt) * 2005-01-25 2017-07-11 Cell Therapeutics Inc Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado

Also Published As

Publication number Publication date
KR20070119622A (ko) 2007-12-20
NZ556726A (en) 2011-04-29
AU2006208199A1 (en) 2006-08-03
EP1841787A2 (en) 2007-10-10
IL184763A0 (en) 2007-12-03
JP2013100292A (ja) 2013-05-23
US8129348B2 (en) 2012-03-06
US20120252717A1 (en) 2012-10-04
WO2006081249A8 (en) 2007-09-13
CA2595695A1 (en) 2006-08-03
IL184763A (en) 2013-05-30
US20090298762A1 (en) 2009-12-03
AU2006208199B2 (en) 2012-06-07
JP2008528002A (ja) 2008-07-31
WO2006081249A3 (en) 2007-02-01
WO2006081249A2 (en) 2006-08-03
MX2007008982A (es) 2007-12-06
WO2006081249A9 (en) 2007-07-26
JP5735194B2 (ja) 2015-06-17
CN103172747A (zh) 2013-06-26
US8748577B2 (en) 2014-06-10
RU2007132188A (ru) 2009-03-10
KR101608083B1 (ko) 2016-04-01
BRPI0606934A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
NO20074267L (no) Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid
ES2397852T3 (es) Antagonistas y conjugados de péptidos CGRP
UA96916C2 (ru) Конъюгат полипептида и синтетически сульфатованого пентасахарида, фармацевтическая композиция на его основе
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2007022512A3 (en) Glycopegylated factor vii and factor viia
WO2005055946A3 (en) Glycopegylated granulocyte colony stimulating factor
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
BRPI0717505B8 (pt) conjugado de peptídeo e formulação farmacêutica
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
SE9901379D0 (sv) Receptor structures
EP3118218A3 (en) Fusion proteins for blood-brain barrier delivery
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
LU91989I2 (fr) Bydureon
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
WO2003049684A3 (en) Pseudo-antibody constructs
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
ES2950137T3 (es) Análogos de hAM15-52 con potencia mejorada frente al receptor de amilina (hAMY3R)
WO2006050930A3 (en) Conjugates with enhanced cell uptake activity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application